101 related articles for article (PubMed ID: 18308171)
1. The balance of risks and benefits of drug-eluting versus bare-metal stents.
Pfisterer M; Brunner-La Rocca HP; Kaiser C
J Am Coll Cardiol; 2008 Mar; 51(9):972; author reply 972-3. PubMed ID: 18308171
[No Abstract] [Full Text] [Related]
2. Comprehensive meta-analysis on drug-eluting stents versus bare-metal stents during extended follow-up.
Roukoz H; Bavry AA; Sarkees ML; Mood GR; Kumbhani DJ; Rabbat MG; Bhatt DL
Am J Med; 2009 Jun; 122(6):581.e1-10. PubMed ID: 19486720
[TBL] [Abstract][Full Text] [Related]
3. Drug eluting or bare metal stent for acute myocardial infarction: an issue of safety?
Finn AV; Nakazawa G; Kolodgie F; Virmani R
Eur Heart J; 2009 Aug; 30(15):1828-30. PubMed ID: 19515688
[No Abstract] [Full Text] [Related]
4. Off-label use of drug-eluting stents putting it in perspective.
Grines CL
J Am Coll Cardiol; 2008 Feb; 51(6):615-7. PubMed ID: 18261679
[No Abstract] [Full Text] [Related]
5. A tale of two stents: perioperative management of patients with drug-eluting coronary stents.
Head DE; Sebranek JJ; Zahed C; Coursin DB; Prielipp RC
J Clin Anesth; 2007 Aug; 19(5):386-96. PubMed ID: 17869994
[TBL] [Abstract][Full Text] [Related]
6. Drug-eluting or bare-metal stents for ST elevation myocardial infarction can observational data balance the risk benefit equation?
Cutlip DE
Circ Cardiovasc Interv; 2008 Dec; 1(3):161-3. PubMed ID: 20031673
[No Abstract] [Full Text] [Related]
7. The safety of drug-eluting stents.
Saia F; Marzocchi A; Branzi A
Ther Adv Cardiovasc Dis; 2008 Feb; 2(1):43-52. PubMed ID: 19124407
[TBL] [Abstract][Full Text] [Related]
8. Bare-metal versus drug-eluting coronary stents.
Agostoni P; Vermeersch P
N Engl J Med; 2008 Jun; 358(23):2516-7; author reply 2517-8. PubMed ID: 18536096
[No Abstract] [Full Text] [Related]
9. Safety of drug-eluting stents.
Windecker S; Jüni P
Nat Clin Pract Cardiovasc Med; 2008 Jun; 5(6):316-28. PubMed ID: 18414453
[TBL] [Abstract][Full Text] [Related]
10. Assessing the landscape of stent thrombosis: the drug-eluting versus bare-metal stent controversy.
Rizik DG; Klassen KJ
Am J Cardiol; 2008 Nov; 102(9 Suppl):4J-11J. PubMed ID: 18928786
[TBL] [Abstract][Full Text] [Related]
11. Comparison of stent thrombosis, myocardial infarction, and mortality following drug-eluting versus bare-metal stent coronary intervention in patients with diabetes mellitus.
Maeng M; Jensen LO; Kaltoft A; Hansen HH; Bøttcher M; Lassen JF; Thayssen P; Krusell LR; Rasmussen K; Pedersen L; Sørensen HT; Johnsen SP; Thuesen L
Am J Cardiol; 2008 Jul; 102(2):165-72. PubMed ID: 18602515
[TBL] [Abstract][Full Text] [Related]
12. The "vulnerable" stent why so dreadful?
Alfonso F
J Am Coll Cardiol; 2008 Jun; 51(25):2403-6. PubMed ID: 18565396
[No Abstract] [Full Text] [Related]
13. [Benefits and risks of drug-eluting stents].
Zijlstra F
Ned Tijdschr Geneeskd; 2007 May; 151(18):1005-7. PubMed ID: 17508683
[TBL] [Abstract][Full Text] [Related]
14. The editor's roundtable: bare-metal stents versus drug-eluting stents-indications and complications.
Friedewald VE; Kastrati A; Roberts WC; Vetrovec GW; Windecker S
Am J Cardiol; 2008 Jul; 102(1):32-9. PubMed ID: 18572032
[No Abstract] [Full Text] [Related]
15. Drug-eluting coronary stents: many meta-analyses, little benefit.
Prescrire Int; 2009 Apr; 18(100):70-4. PubMed ID: 19585727
[TBL] [Abstract][Full Text] [Related]
16. 2-year clinical outcomes after implantation of sirolimus-eluting, paclitaxel-eluting, and bare-metal coronary stents: results from the WDHR (Western Denmark Heart Registry).
Kaltoft A; Jensen LO; Maeng M; Tilsted HH; Thayssen P; Bøttcher M; Lassen JF; Krusell LR; Rasmussen K; Hansen KN; Pedersen L; Johnsen SP; Sørensen HT; Thuesen L
J Am Coll Cardiol; 2009 Feb; 53(8):658-64. PubMed ID: 19232897
[TBL] [Abstract][Full Text] [Related]
17. Clinical outcomes of serolimus-eluting stents versus bare metal stents in ST-segment elevation myocardial infarction patients: a meta-analysis.
Pan XH; Zhong WZ; Xiang MX; Xu G; Shan J; Wang JA
Chin Med J (Engl); 2009 Jan; 122(1):88-92. PubMed ID: 19187623
[TBL] [Abstract][Full Text] [Related]
18. Major adverse cardiac events at follow-up after bare-metal stenting versus drug-eluting stenting in ST-elevated myocardial infarction.
Pierre-Louis B; Aronow WS; Palaniswamy C; Singh T; Ahn C; Asija A; Weiss MB; Kalapatapu K; Pucillo AL; Monsen CE
Am J Cardiol; 2009 Jun; 103(12):1672-4. PubMed ID: 19539074
[TBL] [Abstract][Full Text] [Related]
19. Clinical outcomes after sirolimus-eluting, paclitaxel-eluting, and bare metal stents (from the first phase of the prospective multicenter German DES.DE Registry).
Nienaber CA; Akin I; Schneider S; Senges J; Fetsch T; Tebbe U; Willich SN; Stumpf J; Sabin GV; Silber S; Richardt G; Kuck KH;
Am J Cardiol; 2009 Nov; 104(10):1362-9. PubMed ID: 19892051
[TBL] [Abstract][Full Text] [Related]
20. Drug-eluting stents: do the risks really outweigh the benefits?
Austin D; Pell JP; Oldroyd KG
Heart; 2008 Feb; 94(2):127-8. PubMed ID: 18195113
[No Abstract] [Full Text] [Related]
[Next] [New Search]
